131 related articles for article (PubMed ID: 21130673)
1. SIMD commentary on FDA oversight of laboratory-developed testing.
Vladutiu GD
Mol Genet Metab; 2011 Jan; 102(1):1-3. PubMed ID: 21130673
[No Abstract] [Full Text] [Related]
2. FDA and CLIA oversight of advanced diagnostics and biomarker tests.
Terry SF
Genet Test Mol Biomarkers; 2010 Jun; 14(3):285-7. PubMed ID: 20578940
[No Abstract] [Full Text] [Related]
3. How will the FDA impact the laboratory developed test?
Davis J; Wentz J
Clin Lab Sci; 2007; 20(3):130-1. PubMed ID: 17691668
[No Abstract] [Full Text] [Related]
4. In search of a coherent framework: options for FDA oversight of genetic tests.
Javitt GH
Food Drug Law J; 2007; 62(4):617-52. PubMed ID: 18557224
[No Abstract] [Full Text] [Related]
5. 23andMe and the FDA.
Annas GJ; Elias S
N Engl J Med; 2014 Mar; 370(11):985-8. PubMed ID: 24520936
[No Abstract] [Full Text] [Related]
6. US Food and Drug Administration regulatory oversight of laboratory-developed tests: Commentary on the draft guidance.
Sidawy MK
Cancer Cytopathol; 2015 Oct; 123(10):573-5. PubMed ID: 26042383
[No Abstract] [Full Text] [Related]
7. Bridging the consumer-medical divide: how to regulate direct-to-consumer genetic testing.
Edwards KT; Huang CJ
Hastings Cent Rep; 2014; 44(3):17-9. PubMed ID: 24821248
[No Abstract] [Full Text] [Related]
8. Ensuring quality in genomic medicine: amid the rise in complex laboratory-developed tests, regulatory officials are seeking the right balance on quality assurance.
Nelson B
Cancer Cytopathol; 2014 Dec; 122(12):855-6. PubMed ID: 25510938
[No Abstract] [Full Text] [Related]
9. FDA oversight of laboratory-developed tests will facilitate adoption of pharmacogenetic testing into routine clinical care.
Hillebrenner E; Litwack E; Bradley P; Donigan K; Lowe T; Serrano K; Kelm K; Mansfield E; Gutierrez A
J Clin Pharmacol; 2015 Jul; 55(7):728-30. PubMed ID: 26053648
[No Abstract] [Full Text] [Related]
10. Unapproved tests on a chip.
Nature; 2005 Dec; 438(7069):711. PubMed ID: 16340967
[No Abstract] [Full Text] [Related]
11. Laboratory-Developed Tests: A Legislative and Regulatory Review.
Genzen JR; Mohlman JS; Lynch JL; Squires MW; Weiss RL
Clin Chem; 2017 Oct; 63(10):1575-1584. PubMed ID: 28687634
[TBL] [Abstract][Full Text] [Related]
12. The need for increased oversight of genetic testing: a detailed look at the genetic testing process.
Bonnin DC
Houst J Health Law Policy; 2003; 4(1):149-80. PubMed ID: 16596751
[No Abstract] [Full Text] [Related]
13. The FDA is coming! The FDA is coming!
Leonard DG
Mol Diagn; 2001 Sep; 6(3):153-4. PubMed ID: 11571707
[No Abstract] [Full Text] [Related]
14. An outsider's viewpoint: the FDA should regulate clinical pharmacogenetic/genomic tests, but...
O'Kane D
Clin Pharmacol Ther; 2010 Dec; 88(6):746-8. PubMed ID: 21081942
[No Abstract] [Full Text] [Related]
15. FDA halts 23andMe personal genetic tests. What might this mean for the future of direct-to-consumer testing?
Darnovsky M; Cussins J
MLO Med Lab Obs; 2014 Mar; 46(3):33. PubMed ID: 24696953
[No Abstract] [Full Text] [Related]
16. College of american pathologists proposal for the oversight of laboratory-developed tests.
Vance GH
Arch Pathol Lab Med; 2011 Nov; 135(11):1432-5. PubMed ID: 22032569
[TBL] [Abstract][Full Text] [Related]
17. Gene test kit oversight could prove a mixed blessing for research.
Scudellari M
Nat Med; 2010 Jul; 16(7):728. PubMed ID: 20613733
[No Abstract] [Full Text] [Related]
18. What's brewing in genetic testing.
Nat Genet; 2002 Dec; 32(4):553-4. PubMed ID: 12457183
[No Abstract] [Full Text] [Related]
19. FDA to regulate direct-to-consumer genetic tests.
Brower V
J Natl Cancer Inst; 2010 Nov; 102(21):1610-2, 1617. PubMed ID: 20966430
[No Abstract] [Full Text] [Related]
20. Regulatory agency consideration of pharmacogenomics.
Pendergast MK
Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
